Hikal Ltd – Company Fundamental Analysis

Hikal is a life-sciences contract development and manufacturing company operating across Pharmaceuticals and Crop Protection, with capabilities spanning APIs, intermediates, CDMO and complex chemistry. The business has been going through a difficult phase due to regulatory issues in Pharma and prolonged pricing pressure/inventory correction in Crop Protection. FY26 revenue declined around 8% to ₹1,713 crore, while EBITDA fell 30% to ₹233 crore. The company reported a ₹49 crore consolidated loss, partly aggravated by exceptional charges, including impairment and labour-code related costs. There are, however, signs of operational recovery. In Q1 FY27, revenue increased 5.9% YoY to ₹403 crore and EBITDA improved sharply to ₹37 crore from ₹25 crore, taking the EBITDA margin to 9.2%. Pharma revenue grew 15.2% and the segment returned to profitability at the operating level, while Crop Protection remained weak with a 4.7% revenue decline and segment-level loss. Hikal is also increasing DMF filings to 5–6 annually, expanding differentiated APIs/CDMO capabilities and has commissioned a new cGMP pilot plant in Pune. The investment case is therefore more of a turnaround opportunity than a proven growth story. Recovery in Pharma, normalization of Crop Protection demand, higher-value API/CDMO products and China+1 outsourcing could drive meaningful earnings improvement. On the other hand, the USFDA-related issues, competitive pricing, raw-material inflation, subdued CDMO demand and relatively weak current profitability remain important risks. Overall, Hikal has attractive technical capabilities and a potentially improving business cycle, but I would want to see sustained margin expansion and a return to consistent profitability before treating it as a strong long-term compounder.